News and Perspective

BREAKWATER cohort 3 reports that encorafenib + cetuximab (EC) with FOLFIRI significantly improves objective response rate (ORR) in untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC) compared to standard-of-care (64.4% vs 39.2%). The results support the regimen's potential as a precision-driven frontline option for this aggressive disease subtype.